Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187272 | 0.69 | TDP1 (0.48) | TP53TDP1TRPA1LMNAMAPT | |
| SCHEMBL13366299 | 0.66 | TDP1 (0.44) | TP53TDP1TRPA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6547363 | 0.60 | TDP1 (0.48) | TP53TDP1TRPA1MAPTSMN1; SMN2 | |
| SCHEMBL8756974 | 0.60 | TDP1 (0.48) | TP53TDP1TRPA1LMNACHRM1 | |
| SCHEMBL29883022 | 0.60 | TDP1 (0.48) | TP53TDP1TRPA1MAPTSMN1; SMN2 | |
| SCHEMBL3634469 | 0.59 | KDM4E (0.45) | TP53TDP1SLC6A2KDM4EALDH1A1 | |
| SCHEMBL5716706 | 0.59 | TAS1R3 (0.46) | TP53TDP1LMNASMN1; SMN2KDM4E | |
| SCHEMBL10456035 | 0.59 | TP53 (0.41) | TP53TDP1KDM4EALDH1A1MEN1 | |
| SCHEMBL24771915 | 0.59 | TRPA1 (0.45) | TP53TDP1TRPA1LMNACHRM1 | |
| SCHEMBL19205698 | 0.59 | TRPA1 (0.50) | TP53TDP1TRPA1LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TP53 996/4885TDP1 3922/4885TRPA1 4273/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TP53 996/4885TDP1 3922/4885TRPA1 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.